基于递归分割分析提出的新发转移性鼻咽癌预后亚组及促进局部区域放疗临床决策的回顾性研究
该回顾性研究纳入562例新发转移性鼻咽癌患者(训练队列264例,验证队列298例),采用递归分割分析建立基于受累病灶数和EBV-DNA载量及肝受累的风险分层模型,将患者分为低、中、高危三组,3年总生存率分别为80.4%、42.0%和20.4%(均P<0.05)。低危和中危组加用局部区域调强放疗后行姑息化疗较单纯姑息化疗显著改善总生存(P=0.0032和P=0.0014),而高危组无生存获益(P=0.6)。
要点
- 基于受累病灶数、肝受累和EBV-DNA载量的RPA模型将dmNPC分为低、中、高危三组,3年OS率分别为80.4%、42.0%和20.4%。
- 低危和中危组加用LRRT后行PCT较单纯PCT显著改善OS(P=0.0032和P=0.0014),高危组无获益(P=0.6)。
- 三组患者均在LRRT期间联合同步化疗未见获益(P=0.12、P=0.13和P=0.3),验证队列证实上述结果。
核心结论
- 新型RPA模型在亚组分层中显示出更优的生存区分度,可能有助于为新发转移性鼻咽癌制定更有效的治疗策略。
研究设计与样本
- 回顾性研究,共纳入562例新发转移性鼻咽癌患者,训练队列264例(2007年至2013年),验证队列298例(2014年至2017年)。
- 采用单因素和多因素Cox回归分析确定总生存的独立变量,并基于这些变量应用递归分割分析建立新的风险分层模型。
主要发现
- 经总生存两两比较得出三个风险组:低危(受累病灶≤4个且无肝受累)、中危(受累病灶≤4个伴肝受累或受累病灶>4个且EBV-DNA<62,000 copies/ml)、高危(受累病灶>4个且EBV-DNA>62,000 copies/ml)。
- 三组3年总生存率分别为80.4%、42.0%和20.4%,组间差异均有统计学意义(均P<0.05)。
- 低危组加用局部区域调强放疗后行姑息化疗较单纯姑息化疗显著改善总生存(P=0.0032),中危组同样显著改善(P=0.0014)。
- 高危组加用局部区域调强放疗后行姑息化疗较单纯姑息化疗无生存获益(P=0.6)。
- 三个亚组中患者在局部区域调强放疗期间联合同步化疗均未获益(P=0.12、P=0.13和P=0.3),上述结果在验证队列中得到证实。
关键数值与推荐
- 低危组:受累病灶≤4个且无肝受累,3年总生存率80.4%。
- 中危组:受累病灶≤4个伴肝受累或受累病灶>4个且EBV-DNA<62,000 copies/ml,3年总生存率42.0%。
- 高危组:受累病灶>4个且EBV-DNA>62,000 copies/ml,3年总生存率20.4%。
- 低危组加用LRRT后行PCT对比单纯PCT的OS获益P=0.0032,中危组P=0.0014,高危组P=0.6。
- 三组LRRT期间联合同步化疗对比未联合的P值分别为0.12、0.13和0.3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The high heterogeneity of de novo metastatic nasopharyngeal carcinoma (dmNPC) makes its prognosis and treatment challenging. We aimed to accurately stage dmNPC and assess the patterns of treatment strategies for different risk groups. METHODS: The study enrolled a total of 562 patients, 264 from 2007 to 2013 in the training cohort and 298 from 2014 to 2017 in the validation cohort. Univariate and multivariate Cox regression analyses were conducted to determine the independent variables for overall survival (OS). Recursive partitioning analysis (RPA) was applied to establish a novel risk-stratifying model based on these variables. RESULTS: After pairwise comparisons of OS, three risk groups were generated: low-risk (involved lesions ≤ 4 without liver involvement), intermediate-risk (involved lesions ≤ 4 with liver involvement or involved lesions > 4 with Epstein-Barr virus (EBV)-DNA < 62,000 copies/ml), and high-risk (involved lesions > 4 with EBV-DNA > 62,000 copies/ml). The 3-year OS rate differed significantly between groups (80.4%, 42.0%, and 20.4%, respectively, all P < 0.05). Adding locoregional intensity-modulated radiotherapy (LRRT) followed by palliative chemotherapy (PCT) resulted in a significant OS benefit over PCT alone for the low- and intermediate-risk groups (P = 0.0032 and P = 0.0014, respectively). However, it provided no survival benefits for the high-risk group (P = 0.6). Patients did not benefit from concurrent chemotherapy during LRRT among the three subgroups (P = 0.12, P = 0.13, and P = 0.3, respectively). These results were confirmed with the validation cohort. CONCLUSIONS: The novel RPA model revealed superior survival performance in subgroup stratification and could facilitate more effective treatment strategies for dmNPC.
引用
- Yao Y, Sun X, Huang H, et al. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis. Radiat Oncol. 2023. PMID: 36681832. doi:10.1186/s13014-022-02168-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。